Hemadsorption to Enhance Drug Elimination in Intoxications
Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Apr 3, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment method for patients who have taken too much of certain medications, specifically benzodiazepines or tricyclic antidepressants, and are experiencing serious symptoms like prolonged unconsciousness. The researchers want to see if a special device called a hemadsorber (cytosorb®) can help remove these drugs from the blood more quickly in patients who are in the Intensive Care Unit (ICU). To participate in the study, patients must be over 18, admitted to the ICU, have a low level of consciousness, and have a specific type of drug intoxication along with certain health factors, such as liver or kidney issues that make it harder for their body to eliminate the drugs.
If eligible, participants can expect to have their blood tested both before and after the hemadsorber is used to measure how quickly the drug levels drop. The study is not yet recruiting patients, and it’s important to note that some individuals, such as those who are pregnant or already on dialysis, will not be able to participate. This trial aims to improve the treatment for drug intoxications and may offer valuable insights into how to better manage these serious conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. older than18 years
- • 2. Admission to ICU
- • 3. GCS \< 8 or requiring Flumazenil 8 hours after hospital admission
- • 4. Having an intoxication with a benzodiazepine or tricyclic antidepressant that we can measure/quantify
- • 5. Having a risk factor for delayed drug elimination defined as either Cirrhosis CHILD B/C or chronic kidney insufficiency KDIGO 3b or worse
- Exclusion Criteria:
- • 1. Pregnant patient
- • 2. Patients in chronic dialysis before admission
- • 3. Need for mechanical ventilation for other reasons than intoxications (e.g. pneumonia, neurotrauma)
- • 4. Concomitant pathology requiring continued intravenous sedation
- • 5. Known history of seizures
- • 6. Contra-indication to heparin use
- • 7. DNR restricting the use of mechanical ventilation or dialysis
About Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussel, Brussels Hoofdstedelijk Gewest, Belgium
Patients applied
Trial Officials
Michaël Mekeirele, Medical Doctor
Principal Investigator
Universitair Ziekenhuis Brussel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported